Respiratory syncytial virus (RSV) is associated with a considerable burden of hospitalizations, intensive care unit (ICU) ...

An experimental vaccine has shown promise in protecting against the sexually transmitted disease chlamydia, researchers ...

Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, ...

Strategically, Vivos achieved notable milestones including receiving FDA clearance for its devices to treat moderate to severe obstructive sleep apnea in children, and the introduction of new medical ...

Vivos' cost-cutting initiatives also led to a $1 million or 27% year-over-year reduction in operating loss, versus the third quarter of 2023. For the nine months ended September 30, 2024 operating ...

Completed dosing of 115 participants in a bioavailability and bioequivalence (BA/BE) clinical trial in Australia for IHL-42X, an investigational treatment for obstructive sleep apnea in July 2024.

LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development ...

Therapeutic strides in biotech are advancing promising candidates in clinic to address different stages of sleep apnea and ...

While osteoporosis is much more common in adults over age 60, it can strike younger people too. In fact, according to the ...

A recent study showed that mouth taping, as mimicked by closing the mouth in people with sleep apnea, may not be the cure-all ...

An unhealthy diet and an indolent life are well known causes of heart disease and stroke. But sleep apnea—where people ...

Losing weight, quitting smoking, and limiting alcohol can all help ease obstructive sleep apnea symptoms such as snoring. The ...